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doi:10.1016/j.ejvs.2009.04.019Abstract Objective: To investigate associations between two polymorphisms of the matrix
metalloproteinase-2 gene (MMP2) and the incidence and progression of abdominal aortic aneu-
rysm (AAA).
Methods: Cases and controls were recruited from a trial of screening for AAAs. The association
between two variants of MMP2 (1360C> T, and þ649C> T) in men with AAA (nZ 678) and in
controls (nZ 659) was examined using multivariate analyses. The association with AAA expan-
sion (nZ 638) was also assessed.
Results: In multivariate analyses with adjustments for multiple testing, no association
between either SNP and AAA presence or expansion was detected.
Conclusion: MMP2 1360C> T and þ649C> T variants are not risk factors for AAA.
ª 2009 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.Introduction
Animal models and human aortic wall studies suggest a role
for matrix metalloproteinase-2 (MMP-2) in the pathogenesis
of AAAs.1 However, studies of circulating MMP-2 levels have
failed to find any association with aneurysm diameter or
rate of expansion. Another approach to assessing the role of61 894313333; fax: þ61
.edu.au (P.E. Norman).
ty for Vascular Surgery. PublisheMMP-2 in the cause of AAA is to examine for associations
between functional variants of MMP2 that may influence
life-long levels of circulating MMP-2. In the present study
we investigated a case control series for associations
between two common polymorphisms in MMP2 and the
incidence and progression of AAA.
Report
Details of the Western Australian AAA cohort are described
elsewhere.2 Two MMP2 single nucleotide polymorphismsd by Elsevier Ltd. All rights reserved.
Table 1 Genotyping success rate and distribution of MMP2 genotypes and alleles
SNP Success rate n (%) p-valuea
CC CT TT C T
MMP2 1306C> T Cases 96.5% 385 (57.7) 243 (36.4) 39 (5.8) 1013 (75.9) 321 (24.1) 0.230
Controls 98.9% 372 (56.9) 228 (34.9) 54 (8.3) 972 (74.3) 336 (25.7)
CC CT TT C T
MMP2 þ649C> T Cases 96.3% 600 (90.0) 61 (9.2) 5 (0.8) 1261 (94.7) 71 (5.3) 0.004
Controls 98.0% 554 (85.1) 95 (14.6) 2 (0.3) 1203 (92.4) 99 (7.6)
a Cases vs controls using Fisher’s test.
170 L. Smallwood et al.(SNPs) were chosen for this study; the first (1306C> T,
rs243865) lies within the gene promoter region and the
second (þ649C> T, rs1053605) within the coding region.
The 1306C> T polymorphism has been shown to disrupt
an SP-1 regulatory element which results in the minor (T)
allele displaying significantly lower promoter activity. To
date the functional effects of the þ649C> T coding region
polymorphism, have not been investigated. Both SNPs are
found at >10% frequency in the Caucasian population
(dbSNP; http://www.ncbi.nlm.nih.gov/SNP). The genotyp-
ing and statistical methods were as previously reported.2
Datawere available from 1337 subjects: 659were controls
(aortic diameter <30 mm), 535 with AAAs between 30 and
39 mm, 118 with AAAs between 40 and 49 mm and 25 with
AAAs of 50 mm. The baseline characteristics of the cases
and controls are as previously reported.2 Annual rates of
expansion were available for 638 men with a median follow-
up duration of 5 years. Of these men, 550 were classified as
‘AAAs with slow expansion’ (<3 mm expansion pa) and 88 as
‘AAAs with definite expansion’ (3 mm expansion pa).
Genotyping success rates and frequencies are shown in
Table 1. Amongst controls MMP2þ 649C> T was in HWE,Table 2 Results of the multiple logistic regression modelling fo
Variable O
Age (yrs) 1
Waist Hip Ratio (1.00) 1
Diastolic BP (mmHg) 1
History of/treatment
for hypertension
1
Past history
of stroke
1
Past history
of myocardial infarction
2
Past history
of coronary surgery
2
Vigorous exercise 0
Non-vigorous exercise 0
Never smoked (Baseline)
Ex-smoker 3
Current smoker< 25/day 6
Current smoker 25/day 6
MMP2 þ649C> T CT 0
MMP2 þ649 C> T TT 2but MMP2 1306C> T was not (p-valueZ 0.031). A signifi-
cant difference was found in the frequency of the MMP2
þ649C> T but not MMP2 1306C> T (Table 1). In the
multivariate modelling (Table 2) the CT genotype of MMP2
þ649C> T was associated with a reduced risk of AAA (OR
0.59, 95% CI 0.40, 0.88). As the TT homozygote was very
rare, the polymorphism was modelled under a dominant
genetic model which increased the Odds Ratio to 0.62 (95%
CI: 0.42, 0.92). Following adjustment for multiple testing
for the current SNPs and the results of 5 other SNPs
examined in this case control series,2 the finding with MMP2
þ649C> T became non-significant (q-valueZ 0.10). No
association was detected between either of the SNPs and
the rate of expansion (data not shown).
Discussion
There have been two previous genetic association studies of
MMP2 and AAA: one examined a single SNP (nt-955) in 387
cases and 425 controls3 and the other examined 18 SNPs in
only 51 cases and 48 controls.4 Neither study found any
association between genetic variants and AAA. Althoughr the MMP2 þ649C> T variant
R (95% CI) p-value
.08 (1.05, 1.12) <0.001
.45 (1.08, 1.94) 0.01
.02 (1.01, 1.03) 0.005
.65 (1.26, 2.15) <0.001
.78 (1.05, 2.99) 0.03
.91 (1.94, 4.36) <0.001
.27 (1.44, 3.58) <0.001
.53 (0.39, 0.72) <0.001
.75 (0.57, 0.99) 0.04
.46 (2.50, 4.79) <0.001
.30 (3.59, 11.05) <0.001
.07 (3.19, 11.53) <0.001
.59 (0.40, 0.88) 0.009
.04 (0.31, 13.44) 0.46
MMP2 and Abdominal Aortic Aneurysm 171the present study suggests a protective effect of the MMP2
þ649C> T polymorphism for the presence of AAA, following
adjustment for multiple testing the finding was non-signif-
icant. Furthermore, there was no association with the
expansion of AAAs, and no association between the func-
tional MMP2 1306C> T polymorphism and either AAA
presence or expansion. Different results may have been
obtained with the inclusion of more cases of large AAAs,
however genetic associations with smaller AAAs are more
likely to be informative about factors involved with the
initiation of aneurysm formation.
Our findings are consistent with results from the UK
Small Aneurysm Trial which found no association between
MMP2 1306C> T and the rate of AAA expansion.5 There
was a minor deviation from HWE in the control subjects for
this SNP in the present study. The cause for this was
unclear, however there is no reason to suspect this was
responsible for the negative result.
Despite human data and animal model studies impli-
cating MMP-2 in the pathogenesis of AAA,1 no obvious
association between AAA and circulating levels of MMP-2 or
MMP2 variants have been detected.5 This does not exclude
a role for MMP-2 at the level of the aortic wall but it
suggests that systemically elevated activity or circulating
levels are not involved in the initiation of AAA formation.
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